Teva closes quarterly and lowers revenue expectations;  The stock falls by about 5%

2022 will be another year of declining revenues for Teva Pharmaceuticals. The company today reduced its annual forecast and now expects revenue of $ 15.4-16 billion, compared to the previous forecast which spoke of revenue of $ 15.6-16.2 billion, compared to annual revenue of $ 15.9 billion in 2021. The reduction in the forecast is due to the effects of exchange rates, as well as due to lower expectations for revenue from the original drug Copaxone due to increased competition – $ 750 million, compared to the previous forecast of $ 850 million.

By Editor

Leave a Reply